PDCD1 and head and neck squamous cell carcinoma: In summary, this study demonstrates that elevated systemic inflammation is strongly associated with worse outcomes in patients with HNSCC receiving anti-PD-1 immunotherapy, underscoring the relevance of inflammation in this setting.